Patent classifications
G01N2800/367
ASSAYS AND METHODS FOR TARGETED TREATMENT OF HYDROSALPINX
A method including detecting a presence of at least one analyte in a sample from a subject wherein the at least one analyte is selected from the group consisting of: mesothelin, Galectin-3-binding protein, Clusterin, Polymeric immunoglobulin receptor, Neutrophil gelatinase-associated lipocalin, Leucine-rich alpha-2-glycoprotein, Osteopontin, Alpha-amylase 1, WAP four-disulfide core domain protein 2, Mucin-16, GSTP1, PRDX5, TXN, PRDX6, and SOD1, and determining the subject has hydrosalpinx if the sample comprises an increased level of mesothelin, Galectin-3-binding protein, Clusterin, Polymeric immunoglobulin receptor, Neutrophil gelatinase-associated lipocalin, Leucine-rich alpha-2-glycoprotein, Osteopontin, Alpha-amylase 1, WAP four-disulfide core domain protein 2, and/or Mucin-16 relative to a control, and/or a decreased level of GSTP1, PRDX5, TXN, PRDX6, and/or SOD1, relative to the control, is provided herein. The method may further include if the subject is determined to have hydrosalpinx, administering a hydrosalpinx therapy to the subject.
IDENTIFYING STATUS OF MALE FERTILITY BY DETERMINING SPERM CAPACITATION
This disclosure provides a method for determining male fertility status. The method comprises determining G.sub.M1 distribution patterns following induced sperm capacitation, identifying the frequency of distribution of various patterns, and determining if the frequency distribution of certain G.sub.M1 patterns in response to induced capacitation is altered. Based on the change in the frequency distribution patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.
LIPID PROFILING METHODS FOR PREDICTING POSITIVE PREGNANCY OUTCOME
The present invention relates to a method of determining the outcome of a pregnancy. More particularly, the invention relates to a method of profiling lipids in a fluid sample obtained from a female subject to assess parameters associated with a positive pregnancy outcome.
Methods and Test Kits for Determining Male Fertility Status
This disclosure provides a method for determining male fertility status. The method comprises determining G.sub.M1 localization patterns following induced sperm capacitation, identifying the percentage of various patterns, particularly the ratio of [(AA+APM)/total number of G.sub.M1 localization patterns] and determining if the percentage of certain G.sub.M1 localization patterns in response to induced capacitation is altered. Based on the change in the percentage of localization patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.
METHODS OF PREDICTING ENDOMETRIAL RECEPTIVITY
The present invention relates to methods of predicting endometrial receptivity for embryo implantation in a subject, the method comprising determining a level of podocalyxin in endometrial epithelial cells in the subject. The present invention also relates to methods of monitoring epithelial receptivity and improving epithelial receptivity.
BIOMARKER FOR DIAGNOSING OR PREDICTING REACTIVITY OF OVARY TO FSH AND USE THEREOF
Provided is a biomarker for diagnosing or predicting reactivity of an ovary to FSH and use thereof. According to a composition or a kit for diagnosing or predicting reactivity of an ovary to FSH and a method using the same according to one aspect, the degree of reactivity of the ovary may be easily diagnosed using miRNA present in blood, follicular fluid, granulosa cells, and cumulus cells, and thus it is easy to predict or diagnose symptoms or diseases caused by abnormal reactivity of the ovary to FSH.
METHOD OF EVALUATING FEMALE REPRODUTIVE FUNCTION
A non-invasive method to evaluate the reproductive function in female subjects is disclosed. The method disclosed herein provides assessing female reproductive function and ovarian response based on the number of CGG repeats and AGG interspersion number and pattern on each of the FMR1 gene alleles. Using a mathematical formula, it is possible to calculate an allelic score that differentiates those subjects with a better reproductive performance. This solution can thus be used routinely as a biomarker for predicting infertility or in the selection of ideal ovarian donor candidates.
AUTOMATED EVALUATION OF SPERM MORPHOLOGY
Systems and methods are provided for provided for automatic evaluation of sperm morphology. An image of a semen sample is obtained, and at least a portion of the image is provided to a convolutional neural network classifier. The convolutional neural network classifier evaluates the portion of the image to assign to the portion of the image a set of likelihoods that the portion of the image belongs to a plurality of output classes representing the morphology of sperm within the portion of the image. A metric is assigned to the semen sample based on the likelihoods assigned by the convolutional neural network.
ENDOMETRIAL RECEPTIVITY DETERMINATION
Endometrial receptivity status is determined by measuring, in an uterine fluid sample taken from a woman, the amounts of at least three proteins selected among NNMT, LCN2, PGR, SLC26A2, SLC34A2, TCN1, ENPP3, GRN, STC1, DPP4, MPO, CD55, ELANE, MSLN, CTSB, RNASET2, CRISP3, MVP, MMP26, AOC1 and SDCBP2. The EM receptivity status of the woman is determined based on a comparison of the measured amounts of the at least three proteins with respective control amounts.
Preparation device, diagnostic apparatus, diagnostic kit and diagnostic system
A preparation device for preparing a sample for measurement of a target biomolecule in a probe of a bodily fluid is disclosed that includes a substrate with a capillary network configured to transport the probe of the bodily fluid along the substrate. The substrate may be provided with a fluorescent, reflective or self-luminescent marker adapted to bind with the target biomolecule to emit a reaction radiation when excited by an excitation source. The fluorescent, reflective or self-luminescent marker is adapted, when bound to the target biomolecule and excited by the excitation source, together with the target biomolecule to emit the reaction radiation at an intensity proportional to a quantity of the target biomolecule in the probe of the bodily fluid.